Sarepta's bad week raised questions about its gene therapy program. Here are some answers

Sarepta Therapeutics (SRPT) wasn’t directly implicated in the biotech sector’s credibility crisis last week, but that didn’t stop the company from running into trouble. The “erroneous”

disclosure last Thursday of a serious side effect affecting a single patient with Duchenne muscular dystrophy enrolled in Sarepta’s gene therapy clinical trial sowed confusion, concern, and

anger. The stock price took a hit, recovered, then fell some more. All in, Sarepta shares lost 14%. Monday and a new trading week give Sarepta an opportunity to reset, unless lingering

concerns remain about what exactly happened to its Duchenne gene therapy program and why. Here are eight burning questions and a stab at answers. STAT+ Exclusive Story Already have an

account? Log in THIS ARTICLE IS EXCLUSIVE TO STAT+ SUBSCRIBERS UNLOCK THIS ARTICLE — PLUS IN-DEPTH ANALYSIS, NEWSLETTERS, PREMIUM EVENTS, AND NEWS ALERTS. Already have an account? Log in

Individual plans Group plans View All Plans To read the rest of this story subscribe to STAT+. Subscribe